HUTCHMED (China) ( (HK:0013)) has shared an announcement. HUTCHMED has secured acceptance and priority review in China for its New Drug Application for sovleplenib to treat adults with warm antibody ...

Agios Pharmaceuticals recently released its 10-Q report. The Cambridge, Massachusetts-based biopharmaceutical company focuses ...

FDA grants Priority Review for Johnson & Johnson’s IMAAVY (nipocalimab) in warm autoimmune hemolytic anemia, the first ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application ("NDA") ...

Chinese biopharma Hutchmed today announcesdthat the New Drug Application (NDA) for sovleplenib for the treatment of adult ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA” ...

Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...

If approved, the neonatal Fc receptor blocker would become the first FDA-authorized therapy specifically indicated for patients with wAIHA.

Johnson & Johnson secured fast-track status for its autoimmune drug Imaavy, accelerating the regulatory timeline for what could become the first approved treatment for warm autoimmune hemolytic anemia ...

Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia ...

The U.S. Food and Drug Administration granted Priority Review to Johnson & Johnson’s (NYSE:JNJ) supplemental biologics license application for IMAAVY (nipocalimab-aahu) as a treatment for warm ...